moxifloxacin has been researched along with mexiletine in 6 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (mexiletine) | Trials (mexiletine) | Recent Studies (post-2010) (mexiletine) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 1,488 | 210 | 227 |
| Protein | Taxonomy | moxifloxacin (IC50) | mexiletine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 1.138 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 10 | |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 3 | |
| Sodium channel protein type 2 subunit alpha | Homo sapiens (human) | 2.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Sen, S; Sinha, N | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Blinova, K; Chan, D; Crumb, WJ; Erato, C; Florian, J; Guo, P; Hong, M; Johannesen, L; Lin, J; Mason, JW; Mutlib, A; Sanabria, C; Stockbridge, N; Stohlman, J; Strauss, DG; Ugander, M; Vicente, J; Waite-Labott, K; Wang, J | 1 |
1 review(s) available for moxifloxacin and mexiletine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for moxifloxacin and mexiletine
| Article | Year |
|---|---|
Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial.
Topics: Adult; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cross-Over Studies; Diltiazem; Drug Therapy, Combination; Electrocardiography; Ether-A-Go-Go Potassium Channels; Female; Fluoroquinolones; Heart Rate; Humans; Lidocaine; Long QT Syndrome; Male; Mexiletine; Moxifloxacin; Phenethylamines; Prospective Studies; Sodium Channel Blockers; Sulfonamides; Young Adult | 2016 |
4 other study(ies) available for moxifloxacin and mexiletine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |